Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline receives positive CHMP opinion on Benlysta

GlaxoSmithKline receives positive CHMP opinion on Benlysta

23rd May 2011

GlaxoSmithKline has been granted a recommendation for European regulatory approval of its drug Benlysta as a treatment option for patients with autoantibody-positive active systemic lupus erythematosus.

The company and its partner Human Genome Sciences have won a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for approval of the product as an add-on therapy.

It follows a review of data from two pivotal phase III clinical trials of Benlysta, which satisfied the CHMP that the drug meets the required standard of quality, safety and efficacy.

A final decision is expected to be taken by the European Commission within the next two to three months.

Dr Moncef Slaoui, chairman for research and development at GlaxoSmithKline, said: "A positive recommendation from the CHMP is a major milestone in the clinical development programme for Benlysta."

Earlier this year, GlaxoSmithKline and Valeant Pharmaceuticals were granted European Commission approval for a new epilepsy therapy called Trobalt.ADNFCR-8000103-ID-800552643-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.